<DOC>
	<DOC>NCT01954810</DOC>
	<brief_summary>This study has aim to describe the immune response to the second dose of Japanese encephalitis chimeric vaccine (JECV) in children previously vaccinated with one dose of JECV 5 years ago.</brief_summary>
	<brief_title>Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children</brief_title>
	<detailed_description>This is a prospective study to demonstrate the boosting antibody response in children previously vaccinated with one dose of JECV 5 years ago.</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis, Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>1. Subject who was vaccinated with 1 dose JECV in JEC02 and participated in 5 year followup in JEC05 trial and finished year 5 of followup. 2. Provision of Informed Consent Form signed by at least one parent or other legally acceptable representative. 3. Subject and parent/legally acceptable representative or guardian able to attend all scheduled visits and to comply with all trial procedures 4. In good general health, based on medical history and physical examination 1. Participation in another clinical trial investigating a vaccine which need to have vaccination or blood draw within the 4 weeks preceding the trial vaccination except JEC05 2. Planned participation in another clinical trial during the Day0Day28 period 3. Receipt of live vaccine within 4 weeks preceding the trial vaccination 4. Planned receipt of any vaccine in the 4 weeks following the trial vaccination 5. Receipt of blood or bloodderived products in the past 3 months, which might interfere with assessment of the immune response 6. Known systemic hypersensitivity to any of the vaccine components, or history of a lifethreatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances 7. Chronic illness or any underlying illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion</criteria>
	<gender>All</gender>
	<minimum_age>72 Months</minimum_age>
	<maximum_age>80 Months</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>JECV</keyword>
	<keyword>IMOJEV</keyword>
	<keyword>Booster response</keyword>
	<keyword>Children</keyword>
	<keyword>antibody response</keyword>
	<keyword>Duration</keyword>
</DOC>